Investing.com - Adaptive Biotechnologies (NASDAQ: ADPT) reported third quarter EPS of $-0.220, $0.07 better than the analyst estimate of $-0.290. Revenue for the quarter came in at $46.4M versus the consensus estimate of $40.21M.
Guidance
Adaptive Biotechnologies sees FY 2024 revenue of $143.000M-$145.000M versus the analyst consensus of $172.100M.
Adaptive Biotechnologies's stock price closed at $5.63. It is up 25.950% in the last 3 months and up 24.830% in the last 12 months.
Adaptive Biotechnologies saw 4 positive EPS revisions and 0 negative EPS revisions in the last 90 days. See Adaptive Biotechnologies's stock price’s past reactions to earnings here.
According to InvestingPro, Adaptive Biotechnologies's Financial Health score is "fair performance".
Check out Adaptive Biotechnologies's recent earnings performance, and Adaptive Biotechnologies's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar